Read More

Shattuck Labs To Host Investor Call And Webcast To Share Initial Clinical Trial Data From Phase 1A/B Dose-Expansion Cohorts In Frontline Higher-Risk Myelodysplastic Syndromes And TP53m Acute Myeloid Leukemia And Review Of Dose-Escalation Data From ASH

Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with

STTK

Read More

HiberCell, Inc. Announces Clinical Collaboration With Merck To Evaluate HC-7366, An Activator Of ISR Kinase GCN2, In Combination With WELIREG In A Phase 1b Study Of Patients With Clear Cell Renal Cell Carcinoma

HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced a clinical collaboration with Merck (known as MSD outside the United

MRK

Read More

Melinta Therapeutics & Cidara Therapeutics Announce Publication Of Pooled Data From Phase 3 Pivotal ReSTORE Trial & Phase 2 STRIVE Trial Of REZZAYO For The Treatment Of Candidemia & Invasive Candidiasis In The Lancet ID

Publication reaffirms the proven efficacy and safety of rezafungin dosed once-weekly versus a current standard of care echinocandin dosed once-dailyMelinta Therapeutics, LLC and Cidara Therapeutics, Inc. (NASDAQ:CDTX)

CDTX